Direct oral anticoagulants in extremely obese patients: OK to use?
作者信息
Moll Stephan, Crona Daniel J, Martin Karlyn
机构信息
Division of Hematology-Oncology Department of Medicine University of North Carolina School of Medicine Chapel Hill North Carolina.
Division of Pharmacotherapy University of North Carolina Eshelman School of Pharmacy Chapel Hill North Carolina.
出版信息
Res Pract Thromb Haemost. 2018 Dec 24;3(2):152-155. doi: 10.1002/rth2.12178. eCollection 2019 Apr.
Abstract
摘要
相似文献
1
Direct oral anticoagulants in extremely obese patients: OK to use?直接口服抗凝剂在极度肥胖患者中：可以使用吗？
Res Pract Thromb Haemost. 2018 Dec 24;3(2):152-155. doi: 10.1002/rth2.12178. eCollection 2019 Apr.
2
Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.抗凝治疗和 BMI：高体重对直接口服抗凝剂安全性和疗效的影响。
Future Cardiol. 2022 Sep;18(10):829-837. doi: 10.2217/fca-2021-0146. Epub 2022 Sep 2.
3
Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation.肥胖症心房颤动患者中直接口服抗凝剂的疗效和安全性比较。
Cardiovasc Drugs Ther. 2021 Apr;35(2):261-272. doi: 10.1007/s10557-020-07126-2. Epub 2021 Jan 6.
4
Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review.病态肥胖及减重手术后口服抗凝剂的应用：综述
Am J Med. 2021 Dec;134(12):1465-1475. doi: 10.1016/j.amjmed.2021.07.017. Epub 2021 Aug 15.
5
A comprehensive multi-institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK-432 for patients after gastric cancer surgery. Kyoto Research Group for Digestive Organ Surgery.一项关于胃癌手术后患者口服链球菌制剂OK-432进行术后辅助免疫治疗的多机构综合研究。京都消化器官外科研究小组。
Ann Surg. 1992 Jul;216(1):44-54. doi: 10.1097/00000658-199207000-00007.
6
Use of Direct Oral Anticoagulants in Morbidly Obese Patients.肥胖患者中直接口服抗凝剂的应用。
Pharmacotherapy. 2020 Jan;40(1):72-83. doi: 10.1002/phar.2353. Epub 2019 Dec 30.
7
Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design.直接口服抗凝剂在静脉血栓栓塞患者中不同体重指数组的安全性和有效性：一项回顾性队列设计。
J Thromb Thrombolysis. 2021 Aug;52(2):567-576. doi: 10.1007/s11239-020-02361-8. Epub 2021 Jan 2.
8
Oral direct factor Xa inhibitor gets FDA's OK.口服直接凝血因子Xa抑制剂获美国食品药品监督管理局批准。
Am J Health Syst Pharm. 2011 Aug 15;68(16):1467. doi: 10.2146/news110054.
9
[Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer].[肠道相关淋巴组织的免疫及口服免疫疗法在消化器官癌多学科治疗中的作用]
Nihon Geka Gakkai Zasshi. 1989 Sep;90(9):1436-8.
10
Effectiveness of Direct Oral Anticoagulants in Obese Adults With Atrial Fibrillation: A Systematic Review of Systematic Reviews and Meta-Analysis.直接口服抗凝剂在肥胖房颤成年患者中的有效性：系统评价的系统评价与荟萃分析
Front Cardiovasc Med. 2021 Oct 8;8:732828. doi: 10.3389/fcvm.2021.732828. eCollection 2021.
引用本文的文献
1
Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity.回顾性、多中心分析直接口服抗凝剂治疗肥胖症静脉血栓栓塞症的安全性和有效性。
J Thromb Thrombolysis. 2024 Apr;57(4):603-612. doi: 10.1007/s11239-024-02955-6. Epub 2024 Feb 26.
2
Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data.肥胖与非肥胖患者接受利伐沙班治疗的处方趋势和结局：一项使用真实世界数据的观察性研究。
Eur J Clin Pharmacol. 2023 Dec;79(12):1675-1685. doi: 10.1007/s00228-023-03572-7. Epub 2023 Oct 10.
3
Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.房颤卒中预防的研究机遇：国家心肺血液研究所虚拟研讨会报告。
Stroke. 2023 Mar;54(3):e75-e85. doi: 10.1161/STROKEAHA.121.038273. Epub 2023 Feb 27.
4
Management of venous thromboembolism in morbidly obese patients: a 10-year review.肥胖症患者静脉血栓栓塞的管理：一项为期10年的回顾。
J Thromb Thrombolysis. 2023 Feb;55(2):304-311. doi: 10.1007/s11239-022-02738-x. Epub 2022 Dec 16.
5
Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review.利伐沙班在肥胖受试者中的药代动力学：系统评价。
Clin Pharmacokinet. 2022 Dec;61(12):1677-1695. doi: 10.1007/s40262-022-01160-z. Epub 2022 Oct 6.
6
Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment.医生对低剂量直接口服抗凝剂用于延长阶段静脉血栓栓塞治疗的认知与使用情况
Res Pract Thromb Haemost. 2022 Jun 8;6(4):e12740. doi: 10.1002/rth2.12740. eCollection 2022 May.
7
Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.体重对纳入ETNA-AF-Europe注册研究的房颤患者依度沙班治疗临床结局的影响。
J Clin Med. 2021 Jun 29;10(13):2879. doi: 10.3390/jcm10132879.
8
Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli.中高危肺栓塞后病态肥胖患者的直接口服抗凝治疗
ERJ Open Res. 2021 Feb 1;7(1). doi: 10.1183/23120541.00554-2020. eCollection 2021 Jan.
9
Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity.阿哌沙班与华法林对肥胖和病态肥胖静脉血栓栓塞患者的有效性和安全性比较
J Clin Med. 2021 Jan 8;10(2):200. doi: 10.3390/jcm10020200.
10
Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis.静脉血栓栓塞症研究重点：美国心脏协会和国际血栓与止血学会的科学声明
Res Pract Thromb Haemost. 2020 Jul 8;4(5):714-721. doi: 10.1002/rth2.12373. eCollection 2020 Jul.
本文引用的文献
1
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study.体重超过120公斤的肥胖患者中直接口服抗凝剂的血浆峰值浓度：一项回顾性研究。
Res Pract Thromb Haemost. 2018 Aug 29;2(4):684-688. doi: 10.1002/rth2.12146. eCollection 2018 Oct.
2
Monitoring of Apixaban in a Super Obese Patient.对一名超级肥胖患者的阿哌沙班监测
Am J Med. 2019 Jan;132(1):e15-e16. doi: 10.1016/j.amjmed.2018.08.021. Epub 2018 Sep 7.
3
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.比较病态肥胖人群中房颤患者直接口服抗凝剂与华法林的疗效和安全性。
Ann Pharmacother. 2019 Feb;53(2):165-170. doi: 10.1177/1060028018796604. Epub 2018 Aug 22.
4
The impact of body weight on rivaroxaban pharmacokinetics.体重对利伐沙班药代动力学的影响。
Res Pract Thromb Haemost. 2017 Oct 9;1(2):180-187. doi: 10.1002/rth2.12039. eCollection 2017 Oct.
5
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations.利伐沙班多患者人群群体药代动力学的综合分析。
CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):309-320. doi: 10.1002/psp4.12288. Epub 2018 Apr 16.
6
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).BMI 对日常抗凝治疗中 NOAC 临床结局的影响 - 前瞻性德累斯顿 NOAC 注册研究（NCT01588119）的结果。
Int J Cardiol. 2018 Jul 1;262:85-91. doi: 10.1016/j.ijcard.2018.03.060. Epub 2018 Mar 14.
7
Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016.美国青少年和成年人按性别和年龄划分的肥胖和重度肥胖流行趋势，2007-2008 年至 2015-2016 年。
JAMA. 2018 Apr 24;319(16):1723-1725. doi: 10.1001/jama.2018.3060.
8
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.心房颤动患者临床特征及口服抗凝治疗的国际趋势：来自GARFIELD-AF、ORBIT-AF I和ORBIT-AF II注册研究的结果。
Am Heart J. 2017 Dec;194:132-140. doi: 10.1016/j.ahj.2017.08.011. Epub 2017 Aug 24.
9
Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience.体重 extremes 对接受标准剂量利伐沙班治疗静脉血栓栓塞症患者药物水平的影响；真实生活经验。
需注意，“extremes”在这里可能表述不太准确，或许结合上下文理解会更确切些，比如可能是“极端体重情况”等意思 。
Thromb Res. 2016 Nov;147:32-35. doi: 10.1016/j.thromres.2016.09.010. Epub 2016 Sep 14.
10
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.直接口服抗凝剂抗凝活性的实验室评估：一项系统评价
Chest. 2017 Jan;151(1):127-138. doi: 10.1016/j.chest.2016.08.1462. Epub 2016 Sep 13.
Zotero 插件